Canaccord analyst John Newman lowered the firm’s price target on Regeneron (REGN) to $150 from $170 and keeps a Hold rating on the shares. The firm said its target decrease is driven by more conservative revenue growth and margin expansion given the dilutive impact of the 908 devices asset acquisition, potential tariff-related headwinds and continued pressures on capital purchasing.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron price target lowered to $547 from $575 at BofA
- Regeneron Downgraded to Sell Amid Eylea Sales Decline and Market Pressures
- Regeneron’s odronextamab granted FDA orphan designation
- Resilient Outlook: Regeneron’s Strong Financial Projections Amid Foundation Closure Challenges
- Regeneron price target lowered to $940 from $950 at Guggenheim